Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides

被引:48
作者
Dummer, R [1 ]
Urosevic, M [1 ]
Kempf, W [1 ]
Kazakov, D [1 ]
Burg, G [1 ]
机构
[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
关键词
cutaneous; T-cell lymphoma; mycosis fungoides; immunotherapy; alpha-interferon; imiquimod;
D O I
10.1159/000070962
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Imiquimod is a topical immune response modifier that binds to Toll-like receptors 7 and 8 and induces a-interferon. We locally applied imiquimod 5% cream (Aldara((R))) daily for 2 weeks on a PUVA- and retinoid-resistant plaque on the face of a patient with mycosis fungoides. The diagnosis was based on clinical appearance, histology and molecular studies. Most of the disease manifestations showed a clear remission during PUVA therapy combined with low-dose retinoids. However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:116 / 118
页数:3
相关论文
共 29 条
[1]   Imiquimod: a novel treatment for lentigo maligna [J].
Ahmed, I ;
Berth-Jones, J .
BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (04) :843-845
[2]   Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin 10 mRNA [J].
Asadullah, K ;
Docke, WD ;
Haeussler, A ;
Sterry, W ;
Volk, HD .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 107 (06) :833-837
[3]   Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream [J].
Beutner, KR ;
Geisse, JK ;
Helman, D ;
Fox, TL ;
Ginkel, A ;
Owens, ML .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (06) :1002-1007
[4]   Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma [J].
Bong, AB ;
Bonnekoh, B ;
Franke, I ;
Schön, MP ;
Ulrich, J ;
Gollnick, H .
DERMATOLOGY, 2002, 205 (02) :135-138
[5]   THE THERAPEUTIC ROLE OF INTERFERONS AND MONOCLONAL-ANTIBODIES IN CUTANEOUS T-CELL LYMPHOMAS [J].
BUNN, PA ;
NORRIS, DA .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 95 (06) :S209-S212
[6]   Imiquimod and resiquimod as novel immunomodulators [J].
Dockrell, DH ;
Kinghorn, GR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :751-755
[7]   Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (Interferon-gamma receptor beta-chain) [J].
Dummer, R ;
Heald, PW ;
Nestle, FO ;
Ludwig, E ;
Laine, E ;
Hemmi, S ;
Burg, G .
BLOOD, 1996, 88 (04) :1383-1389
[8]  
Dummer R, 1996, ONKOLOGIE, V19, P226
[9]   EXPRESSION OF BCL-2 PROTEIN AND KI-67 NUCLEAR PROLIFERATION ANTIGEN IN BENIGN AND MALIGNANT CUTANEOUS T-CELL INFILTRATES [J].
DUMMER, R ;
MICHIE, SA ;
KELL, D ;
GOULD, JW ;
HAEFFNER, AC ;
SMOLLER, BR ;
WARNKE, RA ;
WOOD, GS .
JOURNAL OF CUTANEOUS PATHOLOGY, 1995, 22 (01) :11-17
[10]   Sezary Syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1) [J].
Dummer, R ;
Geertsen, R ;
Ludwig, E ;
Niederer, E ;
Burg, G .
LEUKEMIA & LYMPHOMA, 1998, 28 (5-6) :515-+